Market Currents
Cowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from...
-
Tuesday, June 26, 2012, 11:26 AM ETCowen goes against the grain on Celgene (CELG +2.3%) with an upgrade to "outperform" from "neutral," saying that the pharma play has high visibility and revenue predictability. Cowen also assumes an expanded EU label for Revlimid in 2015 despite last week's regulatory setback for the drug. Cowen's note comes after other firms cut their price targets on Celgene.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
